CoChat
Sign Up
Cited by 860

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo

Hirai, Hiroshi, Sootome, Hiroshi, Nakatsuru, Yoko, Miyama, Katsuyoshi, Taguchi, Shunsuke, Tsujioka, Kyoko, Ueno, Yoko, Hatch, Harold, Majumder, Pradip K., Pan, Bo-Sheng, Kotani, Hidehito·2010·Molecular Cancer Therapeutics
DOI 10.1158/1535-7163.mct-09-1012

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The serine/threonine kinase Akt lies at a critical signaling node downstream of phosphatidylinositol-3-kinase and is important in promoting cell survival and inhibiting apoptosis. An Akt inhibitor may be particularly useful for cancers in which increased Akt signaling is associated with reduced sensitivity to cytotoxic agents or receptor tyrosine kinase inhibitors. We evaluated the effect of a novel allosteric Akt inhibitor, MK-2206, in combination with several anticancer agents. In vitro, MK-2206 synergistically inhibited cell proliferation of human cancer cell lines in combination with molecular targeted agents such as erlotinib (an epidermal growth factor receptor inhibitor) or lapatinib (a dual epidermal growth factor receptor/human epidermal growth factor receptor 2 inhibitor). Complementary inhibition of erlotinib-insensitive Akt phosphorylation by MK-2206 was one mechanism of synergism, and a synergistic effect was found even in erlotinib-insensitive cell lines. MK-2206 also showed synergistic responses in combination with cytotoxic agents such as topoisomerase inhibitors (doxorubicin, camptothecin), antimetabolites (gemcitabine, 5-fluorouracil), anti-microtubule agents (docetaxel), and DNA cross-linkers (carboplatin) in lung NCI-H460 or ovarian A2780 tumor cells. The synergy with docetaxel depended on the treatment sequence; a schedule of MK-2206 dosed before docetaxel was not effective. MK-2206 suppressed the Akt phosphorylation that is induced by carboplatin and gemcitabine. In vivo, MK-2206 in combination with these agents exerted significantly more potent tumor inhibitory activities than each agent in the monotherapy setting. These findings suggest that Akt inhibition may augment the efficacy of existing cancer therapeutics; thus, MK-2206 is a promising agent to treat cancer patients who receive these cytotoxic and/or molecular targeted agents. Mol Cancer Ther; 9(7); 1956–67. ©2010 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-09-1012

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 43

  1. Bellacosa, 1991, A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region, Science, 254, 274
  2. Burgering, 1995, Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction, Nature, 376, 599, 10.1038/376599a0 · DOI
  3. Carnero, 2008, The PTEN/PI3K/AKT signaling pathway in cancer, therapeutic implications, Curr Cancer Drug Targets, 8, 187, 10.2174/156800908784293659 · DOI
  4. Tokunaga, 2008, Deregulation of the Akt pathway in human cancer, Curr Cancer Drug Targets, 8, 27, 10.2174/156800908783497140 · DOI
  5. Maira, 2008, Class IA PI3 kinase: from their biological implication in human cancers to drug discovery, Expert Opin Ther Targets, 12, 223, 10.1517/14728222.12.2.223 · DOI
  6. Vivanco, 2002, The phosphatidylinositol 3-kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839 · DOI
  7. Nogueira, 2008, Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis, Cancer Cell, 14, 427, 10.1016/j.ccr.2008.11.003 · DOI · Paper page
  8. Pastukh, 2005, Contribution of the PI 3-kinase/Akt survival pathway toward osmotic preconditioning, Mol Cell Biochem, 269, 59, 10.1007/s11010-005-2536-z · DOI
  9. Mullonkal, 2007, Akt in ischemia and reperfusion, J Invest Surg, 20, 195, 10.1080/08941930701366471 · DOI
  10. West, 2002, Activation of the PI3K/Akt pathway and chemotherapeutic resistance, Drug Resist Updat, 5, 234, 10.1016/S1368-7646(02)00120-6 · DOI
  11. Winograd-Katz, 2006, Cisplatin induces PKB/Akt activation and p38 MAPK phosphorylation of the EGF receptor, Oncogene, 25, 7381, 10.1038/sj.onc.1209737 · DOI
  12. Liu, 2007, AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway, Cancer Res, 67, 6325, 10.1158/0008-5472.CAN-06-4261 · DOI
  13. Bellacosa, 2005, Activation of AKT kinases in cancer: implications for therapeutic targeting, Adv Cancer Res, 94, 29, 10.1016/S0065-230X(05)94002-5 · DOI
  14. Yan, 2006, Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner, Gynecol Oncol, 102, 348, 10.1016/j.ygyno.2005.12.033 · DOI
  15. Clark, 2002, Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells, Mol Cancer Ther, 1, 707
  16. She, 2005, The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells, Cancer Cell, 8, 287, 10.1016/j.ccr.2005.09.006 · DOI
  17. Brognard, 2001, Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation, Cancer Res, 61, 3986
  18. Dillon, 2007, The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer, Oncogene, 26, 1338, 10.1038/sj.onc.1210202 · DOI
  19. Jiang, 2008, PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochim Biophys Acta, 1784, 150, 10.1016/j.bbapap.2007.09.008 · DOI
  20. Lindsley, 2005, Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors, Bioorg Med Chem Lett, 15, 761, 10.1016/j.bmcl.2004.11.011 · DOI
  21. Barnett, 2005, Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors, Biochem J, 385, 399, 10.1042/BJ20041140 · DOI
  22. Defeo-Jones, 2005, Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members, Mol Cancer Ther, 4, 271, 10.1158/1535-7163.271.4.2 · DOI
  23. Yan, 2009, MK-2206: a potent oral allosteric AKT inhibitor, AACR Annual Meeting, Abstract Number: DDT01-1
  24. Ihle, 2009, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res, 69, 143, 10.1158/0008-5472.CAN-07-6656 · DOI
  25. She, 2008, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling, PLoS ONE, 3, e3065, 10.1371/journal.pone.0003065 · DOI
  26. Thomson, 2005, Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition, Cancer Res, 65, 9455, 10.1158/0008-5472.CAN-05-1058 · DOI
  27. Konecny, 2006, Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells, Cancer Res, 66, 1630, 10.1158/0008-5472.CAN-05-1182 · DOI
  28. Pillay, 2009, The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases, Neoplasia, 11, 448, 10.1593/neo.09230 · DOI
  29. Gazdar, 2004, Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?, Trends Mol Med, 10, 481, 10.1016/j.molmed.2004.08.008 · DOI
  30. Yamasaki, 2007, Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt, Cancer Res, 67, 5779, 10.1158/0008-5472.CAN-06-3020 · DOI
  31. Chen, 2008, Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors, Clin Cancer Res, 14, 6730, 10.1158/1078-0432.CCR-08-0581 · DOI
  32. Tokunaga, 2006, Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients, Int J Cancer, 118, 284, 10.1002/ijc.21358 · DOI
  33. Buck, 2008, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors, Cancer Res, 68, 8322, 10.1158/0008-5472.CAN-07-6720 · DOI
  34. Morgillo, 2006, Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib, Cancer Res, 66, 10100, 10.1158/0008-5472.CAN-06-1684 · DOI
  35. Engelman, 2008, Effective use of PI3K and MEK inhibitors to treat mutant K-Ras G12D and PIK3CA H1047R murine lung cancers, Nat Med, 14, 1351, 10.1038/nm.1890 · DOI · Paper page
  36. Yu, 2008, Response and determinants of cancer cell susceptibility to PI3K inhibitors, Cancer Biol Ther, 7, 307, 10.4161/cbt.7.2.5334 · DOI
  37. Harima, 2001, Mutation of the PTEN gene in advanced cervical cancer correlated with tumor progression and poor outcome after radiotherapy, Int J Oncol, 18, 493
  38. O'Reilly, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 · DOI · Paper page
  39. Han, 2007, Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition, Oncogene, 26, 5655, 10.1038/sj.onc.1210343 · DOI
  40. Guertin, 2007, Defining the role of mTOR in cancer, Cancer Cell, 12, 9, 10.1016/j.ccr.2007.05.008 · DOI · Paper page
  41. Hövelmann, 2004, Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells, Brit J Cancer, 90, 2370, 10.1038/sj.bjc.6601876 · DOI
  42. Lee, 2008, Akt1 inhibition by RNA interference sensitizes human non-small cell lung cancer cells to cisplatin, Int J Cancer, 122, 2380, 10.1002/ijc.23371 · DOI
  43. Hollestelle, 2007, Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines, Mol Cancer Res, 5, 195, 10.1158/1541-7786.MCR-06-0263 · DOI

Cited by

See all 860

Metadata

Authors
Hirai, H., Sootome, H., Nakatsuru, Y., Miyama, K., Taguchi, S., Tsujioka, K., Ueno, Y., Hatch, H., Majumder, P. K., Pan, B.-S., & Kotani, H.
Venue
Molecular Cancer Therapeutics
Publisher
American Association for Cancer Research (AACR)
Published
2010-07-01
Volume
9
Issue
7
Pages
1956-1967
ISSN
  • 1535-7163
  • 1538-8514
DOI
10.1158/1535-7163.mct-09-1012
Cited by
860
References
4
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review